Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Barinthus Biotherapeutics Plc ADR (BRNS)

Barinthus Biotherapeutics Plc ADR (BRNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,467
  • Shares Outstanding, K 40,849
  • Annual Sales, $ 0 K
  • Annual Income, $ -66,430 K
  • EBIT $ -71 M
  • EBITDA $ -65 M
  • 60-Month Beta -0.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.30
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.64
  • Most Recent Earnings $-0.27 on 03/13/26
  • Next Earnings Date 05/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.36
  • Number of Estimates 1
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +26.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5120 +7.42%
on 03/24/26
0.6800 -19.12%
on 03/19/26
-0.0341 (-5.84%)
since 02/27/26
3-Month
0.5120 +7.42%
on 03/24/26
0.7700 -28.57%
on 12/29/25
-0.1542 (-21.90%)
since 12/26/25
52-Week
0.5120 +7.42%
on 03/24/26
2.9200 -81.16%
on 07/16/25
-0.5000 (-47.62%)
since 03/28/25

Most Recent Stories

More News
Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

ESQ : 105.95 (-0.54%)
ULY : 5.38 (+0.19%)
BRNS : 0.5500 (unch)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--BRNS, SLAB, MCFT, and MPX

NEW YORK , March 16, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for...

MCFT : 20.59 (-1.20%)
MPX : 7.27 (-0.55%)
BRNS : 0.5500 (unch)
SLAB : 205.85 (-0.04%)
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

FITB : 44.68 (+0.31%)
ADVM : 4.36 (+2.35%)
HBAN : 15.02 (-0.40%)
BRNS : 0.5500 (unch)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB

NEW YORK , Nov. 19, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of...

FITB : 44.68 (+0.31%)
CMA : 88.67 (-4.51%)
HFWA : 25.54 (+1.47%)
BRNS : 0.5500 (unch)
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

AKRO : 54.65 (+0.18%)
NIC : 145.07 (+0.59%)
BRNS : 0.5500 (unch)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS

NEW YORK , Nov. 10, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

NIC : 145.07 (+0.59%)
AKRO : 54.65 (+0.18%)
BRNS : 0.5500 (unch)
CRTAF : 13.1500 (+0.77%)
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

SAN DIEGO , Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical...

BRNS : 0.5500 (unch)
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders

NEW YORK , Oct. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

ETNB : 14.84 (unch)
SWKH : 16.89 (-1.23%)
BRNS : 0.5500 (unch)
VRNT : 20.51 (+1.33%)
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ETNB, TRML, CORZ, BRNS on Behalf of Shareholders

NEW YORK , Oct. 7, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches...

ETNB : 14.84 (unch)
BRNS : 0.5500 (unch)
TRML : 47.98 (unch)
CORZ : 13.91 (-7.70%)
BARINTHUS BIOTHERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics...

BRNS : 0.5500 (unch)

Business Summary

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases. The company's product pipeline includes VTP-300, VTP-200, VTP-1000, VTP-850 and VTP-1100. Barinthus...

See More

Key Turning Points

3rd Resistance Point 0.6637
2nd Resistance Point 0.6293
1st Resistance Point 0.5897
Last Price 0.5500
1st Support Level 0.5157
2nd Support Level 0.4813
3rd Support Level 0.4417

See More

52-Week High 2.9200
Fibonacci 61.8% 2.0001
Fibonacci 50% 1.7160
Fibonacci 38.2% 1.4319
Last Price 0.5500
52-Week Low 0.5120

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.